Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.51 |
| ▸ | CIB1 | Q99828 | 4/20 | 0.50 |
| ▸ | LDLR | P01130 | 2/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.47 |
| ▸ | EPS15 | P42566 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16128404 | 1.00 | CD274 (0.62) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL16128717 | 0.98 | CD274 (0.63) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19345136 | 0.97 | CD274 (0.60) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19345137 | 0.97 | CD274 (0.60) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19345138 | 0.97 | CD274 (0.60) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19754482 | 0.97 | CD274 (0.61) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL17815027 | 0.97 | CD274 (0.64) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19345231 | 0.97 | CD274 (0.64) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL19345247 | 0.96 | CD274 (0.64) | CD274PDCD1KLKB1CIB1LDLR | |
| SCHEMBL18254772 | 0.96 | CD274 (0.65) | CD274PDCD1KLKB1CIB1EPS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850283-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850283-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885KLKB1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.